In the November issue of The Oncology Pharmacist, we provide a highlight of a recent study that was presented at the 2015 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology Annual Meeting on Supportive Care in Cancer on the use of docetaxel plus nintedanib in patients with non–small-cell lung cancer (NSCLC). The study authors found that the combination therapy was well-tolerated, and did not increase the frequency of adverse events associated with antiangiogenic treatment. We also had the opportunity to speak with Anders Mellemgaard, MD, from Herlev University Hospital, Denmark, co-author of the study, about the role of nintedanib in extending survival without reducing the quality of life in patients with NSCLC.
In addition to conference news, we provide valuable insight on the symptom management of patients with chemotherapy and radiotherapy-induced nausea and vomiting, practical information for formulary management and procurement of oncology medications (see page 14), and emerging therapies.
As part of our reader poll (see below), we ask you whether oncology specialty pharmacy promotes coordination of care. Please visit our website, www.TheOncologyPharmacist.com, and let us know whether this is what you have observed in your everyday practice. You can also send comments to info@TheOncologyPharmacist.com.
We hope you will enjoy this issue, and look forward to your feedback.